Everyday Health

FDA Approves Skyrizi (Risankizumab) for Ulcerative Colitis

In studies, the injected medicine helped a significant number of people with UC find relief from moderate to severe symptoms. The FDA has given its okay to the biologic drug Skyrizi (risankizumab) as ...
Seeking Alpha

U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease

NORTH CHICAGO, Ill., June 18, 2024 /PRNewswire/ -- AbbVie (ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI ® (risankizumab-rzaa) for adults with moderately to ...
FiercePharma

AbbVie's rising star Skyrizi nabs key ulcerative colitis FDA approval

AbbVie’s fast-growing Humira successor Skyrizi is already on a roll with skyrocketing sales. Now, the IL-23 inhibitor is poised to take on an even larger share of Humira’s fading market dominance with ...
Seeking Alpha

SKYRIZI® (risankizumab) Now Available for Moderately to Severely Active Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease

SKYRIZI is the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn's disease. 1 "We are so grateful for the approval of SKYRIZI for ...
Nasdaq

AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis

AbbVie ABBV announced that the FDA has granted approval to its blockbuster drug, Skyrizi to treat adults with moderately to severely active ulcerative colitis (UC) in the United States. Skyrizi’s ...
FiercePharma

Docs’ zest for Skyrizi tees AbbVie up for fast ulcerative colitis launch

Physicians have delivered a boost to AbbVie’s hopes of turning Skyrizi into a $17-billion-a-year drug. The 101 gastroenterologists polled by Spherix Global Insights talked up Skyrizi’s promise in ...
Crain's Chicago Business

Skyrizi, a rising star in AbbVie's lineup, approved for ulcerative colitis in Europe

AbbVie has received European Commission approval of its anti-inflammation drug Skyrizi for the treatment of adult patients with moderately to severely active ulcerative colitis, the pharmaceutical ...
Nasdaq

European Commission Approves AbbVie's Skyrizi To Treat Ulcerative Colitis

(RTTNews) - AbbVie Inc. (ABBV) on Friday said the European Commission has approved Skyrizi for the treatment of adults with ulcerative colitis. Ulcerative colitis is a type of inflammatory bowel ...
Medscape

FDA Approves Skyrizi for Ulcerative Colitis

The US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa; AbbVie) for the treatment of moderately to severely active ulcerative colitis in adults. This approval makes it the ...
St. Louis American

U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie’s Portfolio Across Inflammatory Bowel Disease

NORTH CHICAGO, Ill., June 18, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI ® (risankizumab-rzaa) for adults with moderately ...
Monthly Prescribing Reference

FDA Approves Skyrizi for Ulcerative Colitis

Compared with placebo, a greater proportion of patients treated with Skyrizi achieved clinical remission in both the induction and maintenance trials. The Food and Drug Administration (FDA) has ...
MarketWatch

AbbVie says FDA approves Skyrizi for ulcerative colitis

Drug maker AbbVie Inc. on Tuesday said the Food and Drug Administration had approved its drug Skyrizi for adults with moderate to severe forms of ulcerative colitis, broadening the company’s arsenal ...